[1] [1] JIANG Y B, ZHOU X P, WONG H Y,et al. An IL1RL1 genetic variant lowers soluble ST2 levels and the risk effects of APOE-4 in female patients with Alzheimer's disease[J]. Nat Aging, 2022, 2(7):616-634. DOI:10.1038/s43587-022-00241-9.

[2] [2] OKANO M, HIRAHARA K, KIUCHI M,et al. Interleukin-33-activated neuropeptide CGRP-producing memory Th2 cells cooperate with somatosensory neurons to induce conjunctival itch[J]. Immunity, 2022,55(12): 2352-2368. DOI:10.1016/j.immuni.2022.09.016.

[3] [3] PALMER G, LIPSKY B P, SMITHGALL M D,et al. The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33[J]. Cytokine, 2008, 42(3): 358-364. DOI:10.1016/j.cyto.2008.03.008.

[4] [4] GU S Y, WANG R X, ZHANG W T,et al. The production, function, and clinical applications of IL-33 in type 2 inflammation-related respiratory diseases[J/OL]. Front Immunol, 2024, 15: 1436437[2025-02-20]. https://pubmed.ncbi.nlm.nih.gov/39301028/. DOI:10.3389/fimmu.2024.1436437.

[5] [5] ENGLAND E, GARETH REES D, SCOTT I C,et al. Tozorakimab(MEDI3506): an anti-IL-33 antibody that inhibits IL-33 signallingviaST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction[J/OL]. Sci Rep, 2023, 13(1): 9825[2025-02-20]. https://pubmed.ncbi.nlm.nih.gov/37330528/. DOI:10.1038/s41598-023-36642-y.

[6] [6] SONG M J, YANG J Y, DI M P,et al. Alarmin IL-33 orchestrates antitumoral T cell responses to enhance sensitivity to 5-fluorouracil in colorectal cancer[J]. Theranostics, 2023, 13(5): 1649-1668. DOI:10.7150/thno.80483.

[7] [7] WU S X, JIAO J, WANG N,et al. Tregs ST2 deficiency enhances the abscopal anti-tumor response induced by microwave ablation[J/OL]. Int Immunopharmacol, 2024, 143(Pt 2): 113330[2025-02-20]. https://pubmed.ncbi.nlm.nih.gov/39423663/. DOI:10.1016/j.intimp.2024.113330.

[8] [8] DE SALVO C, PASTORELLI L, PETERSEN C P,et al. Interleukin 33 triggers early eosinophil-dependent events leading toMetaplasiain a chronic model of gastritis-prone mice[J]. Gastroenterology,2021, 160(1): 302-316.e7. DOI:10.1053/j.gastro.2020.09.040.

[9] [9] ZENG X, YANG M H, YE T B,et al. Mitochondrial GRIM-19 loss in parietal cells promotes spasmolytic polypeptide-expressingMetaplasiathrough NLR family pyrin domain-containing 3 (NLRP3)-mediated IL-33 activationviaa reactive oxygen species (ROS)-NRF2-Heme oxygenase-1 (HO-1)-NF-кB axis[J]. Free Radic Biol Med, 2023, 202:46-61. DOI:10.1016/j.freeradbiomed.2023.03.024.

[10] [10] LIU K W, HUANG H X, XIONG M Y,et al. IL-33 accelerates chronic atrophic gastritis through AMPK-ULK1 axis mediated autolysosomal degradation of GKN1[J]. Int J Biol Sci, 2024, 20(6):2323-2338. DOI:10.7150/ijbs.93573.

[11] [11] MOLFETTA R, LECCE M, MILITO N D,et al. SCF and IL-33 regulate mouse mast cell phenotypic and functional plasticity supporting a pro-inflammatory microenvironment[J/OL]. Cell Death Dis, 2023, 14(9): 616[2025-02-20]. https://pubmed.ncbi.nlm.nih.gov/37730723/. DOI:10.1038/s41419-023-06139-7.

[12] [12] HE Z X, CHEN L L, SOUTO F O,et al. Epithelial-derived IL-33 promotes intestinal tumorigenesis in ApcMin/+ mice[J/OL]. Sci Rep,2017, 7(1): 5520[2025-02-20]. https://pmc.ncbi.nlm.nih.gov/articles/PMC5511216. DOI:10.1038/s41598-017-05716-z.

[13] [13] UEMURA K, KATAYAMA K I, NISHIOKA T,et al. Dynamics of immune cell infiltration and fibroblast-derived IL-33/ST2 axis induction in a mouse model of post-surgical lymphedema[J/OL]. Int J Mol Sci, 2025, 26(3): 1371[2025-02-20]. https://pubmed.ncbi.nlm.nih.gov/39941140/. DOI:10.3390/ijms26031371.

[14] [14] LAMORTE S, QUEVEDO R, JIN R,et al. Lymph node macrophages drive immune tolerance and resistance to cancer therapy by induction of the immune-regulatory cytokine IL-33[J/OL]. Cancer Cell, 2025: S1535-6108(25)00069-8[2025-02-20]. https://pubmed.ncbi.nlm.nih.gov/40054466/. DOI:10.1016/j.ccell.2025.02.017.

[15] [15] HUANG N, CUI X, LI W,et al. IL-33/ST2 promotes the malignant progression of gastric cancerviathe MAPK pathway[J/OL]. Mol Med Rep, 2021, 23(5): 361[2025-02-20]. https://pmc.ncbi.nlm.nih.gov/articles/PMC7985998/. DOI:10.3892/mmr.2021.12000.

[16] [16] AKIMOTO M, SUSA T K, OKUDAIRA N,et al. Hypoxia induces downregulation of the tumor-suppressive sST2 in colorectal cancer cellsviathe HIF-nuclear IL-33-GATA3 pathway[J/OL]. Proc Natl Acad Sci USA, 2023, 120(18): e2218033120[2025-02-20]. https://pubmed.ncbi.nlm.nih.gov/37094129/. DOI:10.1073/pnas.2218033120.

[17] [17] LIU Q H, ZHANG J W, XIA L,et al. Clinical implications of interleukins-31, 32, and 33 in gastric cancer[J]. World J Gastrointest Oncol, 2022, 14(9): 1808-1822. DOI:10.4251/wjgo.v14.i9.1808.

[18] [18] HU W W, LI X D, LI Q,et al. Interleukin-33 expression does not correlate with survival of gastric cancer patients[J]. Pathol Oncol Res, 2017, 23(3): 615-619. DOI:10.1007/s12253-016-0167-1.

[19] [19] GE Y X, JANSON V, DONG Z G,et al. Role and mechanism of IL-33 in bacteria infection related gastric cancer continuum: From inflammation to tumor progression[J/OL]. Biochim Biophys Acta Rev Cancer, 2025, 1880(2): 189296[2025-02-20]. https://pubmed.ncbi.nlm.nih.gov/40058506/. DOI:10.1016/j.bbcan.2025.189296.

[20] [20] SHAO L M, LI P W, YE J,et al. Risk of gastric cancer among patients with gastric intestinalMetaplasia[J]. Int J Cancer, 2018, 143(7): 1671-1677. DOI:10.1002/ijc.31571.

[21] [21] BAI X, GUO Y R, ZHU X M,et al. Autoimmune diseases and risk of gastrointestinal cancer: an umbrella review of meta-analyses of observational studies[J]. Int J Surg, 2025, 111(2): 2273-2282. DOI:10.1097/JS9.0000000000002219.

[22] [22] CALAFIORE M, FU Y Y, VINCI P,et al. A tissue-intrinsic IL-33/EGF circuit promotes epithelial regeneration after intestinal injury[J/OL]. Nat Commun, 2023, 14(1): 5411[2025-02-20]. https://pubmed.ncbi.nlm.nih.gov/37669929/. DOI:10.1038/s41467-023-40993-5.

[23] [23] YUAN C Y, RAYASAM A, MOE A,et al. Interleukin-9 production by type 2 innate lymphoid cells induces Paneth cellMetaplasiaand small intestinal remodeling[J/OL]. Nat Commun, 2023, 14(1): 7963[2025-02-20]. https://pubmed.ncbi.nlm.nih.gov/38042840/. DOI:10.1038/s41467-023-43248-5.

[24] [24] HE P Y, WU M Y, ZHENG L Y,et al. Interleukin-33/serum stimulation-2 pathway: Regulatory mechanisms and emerging implications in immune and inflammatory diseases[J]. Cytokine Growth Factor Rev,2024, 76: 112-126. DOI:10.1016/j.cytogfr.2023.12.001.

[25] [25] SUN R Z, ZHAO H Y, GAO D S,et al. Amphiregulin couples IL1RL1+ regulatory T cells and cancer-associated fibroblasts to impede antitumor immunity[J/OL]. Sci Adv, 2023, 9(34): eadd7399[2025-02-20]. https://pubmed.ncbi.nlm.nih.gov/37611111/. DOI:10.1126/sciadv.add7399.

[26] [26] ZHANG T, TANG X D. BeyondMetaplasia: unraveling the complex pathogenesis of autoimmune atrophic gastritis and its implications for gastric cancer risk[J/OL]. QJM, 2025: hcaf028[2025-02-20]. https://pubmed.ncbi.nlm.nih.gov/39854274/. DOI:10.1093/qjmed/hcaf028.

[27] [27] GUAN R Y, PAN M X, XU X Y,et al. Interleukin-33 potentiates TGF- signaling to regulate intestinal stem cell regeneration after radiation injury[J/OL]. Cell Transplant, 2023, 32:9636897231177377[2025-02-20]. https://pubmed.ncbi.nlm.nih.gov/37291802/. DOI:10.1177/09636897231177377.

[28] [28] JOU E, RODRIGUEZ-RODRIGUEZ N, FERREIRA A F,et al. An innate IL-25-ILC2-MDSC axis creates a cancer-permissive microenvironment forApcmutation-driven intestinal tumorigenesis[J/OL]. Sci Immunol, 2022, 7(72): eabn0175[2025-02-20]. https://pubmed.ncbi.nlm.nih.gov/35658010/. DOI:10.1126/sciimmunol.abn0175.

[29] [29] CHEN Z J, LUO J L, LI J,et al. Interleukin-33 promotes serotonin release from enterochromaffin cells for intestinal homeostasis[J]. Immunity, 2021, 54(1): 151-163. DOI:10.1016/j.immuni.2020.10.014.

[30] [30] LIAO X J, XIE H T, YU S J. Calycosin prevents NLRP3-induced gut fibrosis by regulating IL-33/ST2 axis[J/OL]. Heliyon, 2024, 10(9):e30240[2025-02-20]. https://pubmed.ncbi.nlm.nih.gov/38726105/. DOI:10.1016/j.heliyon.2024.e30240.

[31] [31] LV Y P, TIAN W Q, TENG Y S,et al. Tumor-infiltrating mast cells stimulate ICOS+ regulatory T cells through an IL-33 and IL-2 axis to promote gastric cancer progression[J]. J Adv Res, 2024, 57: 149-162. DOI:10.1016/j.jare.2023.04.013.

[32] [32] ZHOU Y X, JI Y, WANG H G,et al. IL-33 promotes the development of colorectal cancer through inducing tumor-infiltrating ST2L+ regulatory T cells in mice[J/OL]. Technol Cancer Res Treat, 2018, 17:1533033818780091[2025-02-20]. https://pubmed.ncbi.nlm.nih.gov/29950152/. DOI:10.1177/1533033818780091.

[33] [33] LI Y K, SHI J, QI S S,et al. IL-33 facilitates proliferation of colorectal cancer dependent on COX2/PGE2[J/OL]. J Exp Clin Cancer Res, 2018, 37(1): 196[2025-02-20]. https://pubmed.ncbi.nlm.nih.gov/30119635/. DOI:10.1186/s13046-018-0839-7.

[34] [34] OBATA-NINOMIYA K, DE JESUS CARRION S, HU A,et al. Emerging role for thymic stromal lymphopoietin-responsive regulatory T cells in colorectal cancer progression in humans and mice[J/OL]. Sci Transl Med, 2022, 14(645): eabl6960[2025-02-20]. https://pubmed.ncbi.nlm.nih.gov/35584230/. DOI:10.1126/scitranslmed.abl6960.

[35] [35] TRAN C P, SCURR M, O'CONNOR L,et al. IL-33 promotes gastric tumour growth in concert with activation and recruitment of inflammatory myeloid cells[J]. Oncotarget, 2022, 13: 785-799. DOI:10.18632/oncotarget.28238.

[36] [36] WACHTENDORF S, JONIN F, OCHEL A,et al. The ST2+ Treg/amphiregulin axis protects from immune-mediated hepatitis[J/OL]. Front Immunol, 2024, 15: 1351405[2025-02-20]. https://pubmed.ncbi.nlm.nih.gov/38571949/. DOI:10.3389/fimmu.2024.1351405.

[37] [37] EISSMANN M F, DIJKSTRA C, JARNICKI A,et al. IL-33-mediated mast cell activation promotes gastric cancer through macrophage mobilization[J/OL]. Nat Commun, 2019, 10(1): 2735[2025-02-20]. https://pubmed.ncbi.nlm.nih.gov/31227713/. DOI:10.1038/s41467-019-10676-1.

[38] [38] PASTILLE E, WASMER M H, ADAMCZYK A,et al. The IL-33/ST2 pathway shapes the regulatory T cell phenotype to promote intestinal cancer[J]. Mucosal Immunol, 2019, 12(4): 990-1003. DOI:10.1038/s41385-019-0176-y.

[39] [39] ERCOLANO G, GOMEZ-CADENA A, DUMAUTHIOZ N,et al. PPAR drives IL-33-dependent ILC2 pro-tumoral functions[J/OL]. Nat Commun, 2021, 12(1): 2538[2025-02-20]. https://pubmed.ncbi.nlm.nih.gov/33953160/. DOI:10.1038/s41467-021-22764-2.

[40] [40] FANG M, LI Y K, HUANG K,et al. IL33 promotes colon cancer cell stemnessviaJNK activation and macrophage recruitment[J]. Cancer Res, 2017, 77(10): 2735-2745. DOI:10.1158/0008-5472. CAN-16-1602.

[41] [41] PISANI L F, TONTINI G E, GENTILE C,et al. Proinflammatory interleukin-33 induces dichotomic effects on cell proliferation in normal gastric epithelium and gastric cancer[J/OL]. Int J Mol Sci,2021, 22(11): 5792[2025-02-20]. https://pubmed.ncbi.nlm.nih.gov/34071419/. DOI:10.3390/ijms22115792.

[42] [42] ARRIZABALAGA L, RISSON A, EZCURRA-HUALDE M,et al. Unveiling the multifaceted antitumor effects of interleukin 33[J/OL]. Front Immunol, 2024, 15: 1425282[2025-02-20]. https://pubmed.ncbi.nlm.nih.gov/38881897/. DOI:10.3389/fimmu.2024.1425282.

[43] [43] CHE K Y, LUO Y T, SONG X R,et al. Macrophages reprogramming improves immunotherapy of IL-33 in peritoneal metastasis of gastric cancer[J]. EMBO Mol Med, 2024, 16(2): 251-266. DOI:10.1038/s44321-023-00012-y.

[44] [44] PERRI G, VILAS BOAS V G, NOGUEIRA M R S,et al. Interleukin 33 supports squamous cell carcinoma growthviaa dual effect on tumour proliferation, migration and invasion, and T cell activation[J/OL]. Cancer Immunol Immunother, 2024, 73(6): 110[2025-02-20]. https://pubmed.ncbi.nlm.nih.gov/38662248/. DOI:10.1007/s00262-024-03676-8.

[45] [45] LUO P, DENG S R, YE H,et al. The IL-33/ST2 pathway suppresses murine colon cancer growth and metastasis by upregulating CD40 L signaling[J/OL]. Biomed Pharmacother, 2020, 127: 110232[2025-02-20]. https://pubmed.ncbi.nlm.nih.gov/32559854/. DOI:10.1016/j.biopha.2020.110232.

[46] [46] CHEN J T, ZHAO Y H, JIANG Y X,et al. Interleukin-33 contributes to the induction of Th9 cells and antitumor efficacy by dectin-1-activated dendritic cells[J/OL]. Front Immunol, 2018, 9:1787[2025-02-20]. https://pubmed.ncbi.nlm.nih.gov/30108595/. DOI:10.3389/fimmu.2018.01787.

[47] [47] KIENZL M, HASENOEHRL C, VALADEZ-COSMES P,et al. IL-33 reduces tumor growth in models of colorectal cancer with the help of eosinophils[J/OL]. Oncoimmunology, 2020, 9(1): 1776059[2025-02-20]. https://pubmed.ncbi.nlm.nih.gov/32923137/. DOI:10.1080/2162402X.2020.1776059.

[48] [48] EISSMANN M F, DIJKSTRA C, WOUTERS M A,et al. Interleukin 33 signaling restrains sporadic colon cancer in an interferon--dependent manner[J]. Cancer Immunol Res, 2018, 6(4): 409-421. DOI:10.1158/2326-6066.CIR-17-0218.

[49] [49] ZHU Y Q, LU Y X, ZHU Y F,et al. ST2L promotes VEGFA-mediated angiogenesis in gastric cancer by activating TRAF6/PI3K/Akt/NF-B pathwayviaIL-33[J/OL]. Sci Rep, 2024, 14(1): 26393[2025-02-20]. https://pubmed.ncbi.nlm.nih.gov/39488565/. DOI:10.1038/s41598-024-76763-6.

[50] [50] ZHOU Q, WU X Y, WANG X F,et al. The reciprocal interaction between tumor cells and activated fibroblasts mediated by TNF-/IL-33/ST2L signaling promotes gastric cancer metastasis[J]. Oncogene,2020, 39(7): 1414-1428. DOI:10.1038/s41388-019-1078-x.

[51] [51] DUAN Y T, XU Y H, DOU Y,et al.Helicobacter pyloriand gastric cancer: mechanisms and new perspectives[J/OL]. J Hematol Oncol,2025, 18(1): 10[2025-02-20]. https://pubmed.ncbi.nlm.nih.gov/39849657/. DOI:10.1186/s13045-024-01654-2.

[52] [52] KWON J W, SEOK S H, KIM S,et al. A synergistic partnership between IL-33/ST2 and Wnt pathway through Bcl-xL drives gastric cancer stemness and metastasis[J]. Oncogene, 2023, 42(7): 501-515. DOI:10.1038/s41388-022-02575-5.

[53] [53] CHEN L J, SUN R Z, XU J C,et al. Tumor-derived IL33 promotes tissue-resident CD8+ T cells and is required for checkpoint blockade tumor immunotherapy[J]. Cancer Immunol Res, 2020, 8(11): 1381-1392. DOI:10.1158/2326-6066.CIR-19-1024.

[54] [54] JOVANOVIC M Z, GELLER D A, GAJOVIC N M,et al. Dual blockage of PD-L/PD-1 and IL33/ST2 axes slows tumor growth and improves antitumor immunity by boosting NK cells[J/OL]. Life Sci, 2022, 289: 120214[2025-02-20]. https://pubmed.ncbi.nlm.nih.gov/34890591/. DOI:10.1016/j.lfs.2021.120214.

[55] [55] NAN Y Y, BAI Y, HU X Z,et al. Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy[J/OL]. J Immunother Cancer, 2024, 12(9):e009236[2025-02-20]. https://pubmed.ncbi.nlm.nih.gov/39231544/. DOI:10.1136/jitc-2024-009236.

[56] [56] BROG R A, FERRY S L, SCHIEBOUT C T,et al. Superkine IL-2 and IL-33 armored CAR T cells reshape the tumor microenvironment and reduce growth of multiple solid tumors[J]. Cancer Immunol Res, 2022,10(8): 962-977. DOI:10.1158/2326-6066.CIR-21-0536.